Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal CancerEric X. Chen, Chris J. O’Callaghan|JAMA Oncology|2020Cited by 389
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b studyJames J. Harding, Sebastián Mondaca, Lequn Bao et al.|The Lancet Oncology|2023Cited by 243
Association of Neurocognitive Deficits With Radiotherapy or Chemoradiotherapy for Patients With Head and Neck CancerAlona Zer, Lori J. Bernstein, Gregory R. Pond et al.|JAMA Otolaryngology–Head & Neck Surgery|2017Cited by 56